| ID Source | ID |
|---|---|
| PubMed CID | 11954258 |
| CHEMBL ID | 2359670 |
| SCHEMBL ID | 466913 |
| MeSH ID | M0021337 |
| Synonym |
|---|
| unii-hp46xk89xb |
| thiethylperazine malate [usp] |
| thietylperazine malate |
| hp46xk89xb , |
| torecan |
| torecan (tn) |
| D02610 |
| 52239-63-1 |
| thiethylperazine malate (jan) |
| NCGC00017115-01 |
| cas-52239-63-1 |
| einecs 257-780-2 |
| thiethylperazine dimalate |
| 10h-phenothiazine, 2-(ethylthio)-10-(3-(4-methyl-1-piperazinyl)propyl)-, 2-hydroxy-1,4-butanedioate (1:2) |
| norzine ampuls |
| thiethylperazine malate |
| malic acid, compound with 2-(ethylthio)-10-(3-(4-methylpiperazin-1-yl)propyl)-10h-phenothiazine (2:1) |
| 2-(ethylthio)-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine malate (1:2) |
| HMS1571E18 |
| HMS2098E18 |
| tox21_110784 |
| dtxsid1045586 , |
| dtxcid9025586 |
| thiethylperazine malate [jan] |
| thiethylperazine malate [orange book] |
| thiethylperazine dimalate [mi] |
| thiethylperazine malate [mart.] |
| 2-(ethylthio)-10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazine malate (1:2) |
| CCG-221068 |
| 2-ethylsulfanyl-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine;2-hydroxybutanedioic acid |
| SCHEMBL466913 |
| CHEMBL2359670 |
| sr-01000841243 |
| SR-01000841243-2 |
| HMS3715E18 |
| Q27280042 |
| thiethylperazine malate (usp) |
| thiethylperazine malate (mart.) |
| hydroxybutanedioic acid compd. with 2-(ethylthio)-10-[3-(4-methyl-1-piperazinyl)propyl]-10h-phenothiazine (2:1) |
| 2-(ethylthio)-10-[3-(4-methyl-1-piperazinyl)propyl]-10h-phenothiazine hydroxybutanedioate (1:2) |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 12.0683 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 0.1413 | 0.0123 | 7.9835 | 43.2770 | AID1346984 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 0.9099 | 0.0002 | 14.3764 | 60.0339 | AID720691 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 8.9125 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 3.2013 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.13) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||